COGT: cogentbio.com Expected earnings per share growth for next year

Public company logo of Cogent Biosciences (COGT)

This chart helps assess the viability of Cogent Biosciences (COGT), given the lack of revenue and dependence on drug registration. After evaluating the net income per share expectations on GURU.Markets, we find that 48.70 determines the current status of this parameter. The business relies on creating unique kinase inhibitors to combat mastocytosis, however, massive R&D expenditures and uncertainty regarding final-stage trials maintain high risks.

Cogent Biosciences Inc (COGT): Net earnings per share change forecast for next year from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company Cogent Biosciences Inc (COGT)

- share price and consensus valuation forecast:
Fundamental company valuation:COGT, cogentbio.com
Finished products of Cogent Biosciences, Inc.

This indicator captures the consensus earnings per share (EPS) forecast, allowing investors to gauge market expectations and avoid entering the asset at a valuation peak. By analyzing the trend of forward EPS estimates for Cogent Biosciences (COGT), one can assess how strict FDA regulations and R&D expenditures will impact the company's future profitability amidst intense competition.

Analysis of competing companies

VRTX (Vertex) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year ALNY (Alnylam)|Expected earnings per share growth for next year INSM (Insmed)|UTHR (United Therapeutics Corp) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year BioMarin BMRN|BBIO (BridgeBio Pharma Inc) - Net earnings per share change forecast for next year|BGM Group Ltd - Earnings growth forecast for next year|Expected earnings per share trend next year XERS (Xeris Biopharma)|KROS: Earnings growth forecast for next year|Arcturus Therapeutics Inc (ARCT) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Eton Pharma|KMDA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year fulcrumtx.com (FULC)|Expected earnings per share growth for next year Abeona Therapeutics Inc. ABEO|Earnings growth forecast for next year MREO (Mereo BioPharma Group)|PLX (Protalix BioTherapeutics Inc.) - Net earnings per share change forecast for next year|PLRX - Net earnings per share growth forecast for next year|APLT - Earnings growth forecast for next year|RNTX: Earnings growth forecast for next year|Expected net earnings per share growth next year Gelteq Limited Inc (GELS)|Expected earnings per share growth for next year AYTU|Expected net earnings per share growth next year chemomab.com CMMB|Expected earnings per share growth for next year SRXH (SRx Health Solutions Inc)|PLRZ - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Aeterna Zentaris AEZS|Cyclo Therapeutics, Inc. (CYTH) - Expected net earnings per share growth next year|INZY - Net earnings per share growth forecast for next year|Expected earnings per share trend next year RPHM (Reneo Pharmaceuticals Inc.)|COSCIENS Biopharma Inc. (CSCI) - Net earnings per share growth forecast for next year